Wells Fargo & Company Kiora Pharmaceuticals Inc Transaction History

Wells Fargo & Company

  • $434 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022
BUY
$0.36 - $0.68 $2 - $4
7 Added 8.97%
85 $0
Q4 2021

Feb 14, 2022
BUY
$0.86 - $2.11 $67 - $164
78 New
78 $0

About KIORA PHARMACEUTICALS INC

KPRX Quotes by TradingView
  • Ticker KPRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 919,078
  • Market Cap $3.1M
  • Description
  • Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients ...
More about KPRX
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email